We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Discover how the new framework will improve the way of designing and planning clinical trials and performing primary analyses and sensitivity analyses. The European Medicines Agency (EMA) adopted the E9(R1) addendum on estimands and sensitivity analysis in clinical trials effective July 30 2020. Bringing clarity to the concept of estimands and the key issues debated in E9(R1) will help to understand their purpose and impact on study design, statistical analyses and the study outcome.
The webinar is hosted by Kristina Bondareva, the Head of Biostatistics at OCT Clinical.
 Addendum on Estimands and Sensitivity Analysis&p%5Bsummary%5D=DESC&p%5Burl%5D=https://oct-clinicaltrials.com/kr/resources/webinars/ich-e9(r1)-addendum-on-estimands-and-sensitivity-analysis&p%5Bimages%5D%5B0%5D=https://oct-clinicaltrials.com/kr/assets/images/1311/1311-pnm6u0-ICH-E9-R1-Addendum-on-Estimands-Sensitivity-Analysis.jpg)
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
